Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve®

Launched by P+F PRODUCTS + FEATURES GMBH · Oct 29, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at how well patients with severe tricuspid regurgitation (a condition where the heart's tricuspid valve doesn't close properly) do after being treated with a special device called the TricValve® Transcatheter Bicaval Valves System. The study will follow patients over time to see how the treatment affects their heart health and overall well-being.

To be eligible for this trial, patients must have successfully received the TricValve treatment and agreed to participate by giving their consent. There are no specific exclusions, so anyone who meets these criteria can join. Participants in this study can expect regular follow-ups to monitor their progress after the treatment, helping doctors understand the long-term effects of this innovative therapy. This research is important as it aims to improve care for people with heart valve diseases.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Successful treatment with TricValve Transcatheter Bicaval Valves System
• • Patient/patient's authorized legal guardian gives his consent to participate in the study and signed the corresponding inform consent
• Exclusion Criteria:
• • no exclusion criterion